OptiSeq™ Pan-Cancer Panel (65 Gene) | DiaCarta, Inc.

OptiSeq™ Pan-Cancer Panel Service (65-Gene)

Sample to Clinical Report within 10 days, Performed in a CLIA-Certified Laboratory

DiaCarta offers a sample-to-report OptiSeq™ Targeted Sequencing cancer diagnostic service at its state-of-art CLIA certified facility. The liquid biopsy/FFPE sample prep workflow provides clients with fast turnaround time and accurate VAF detection process. Powered by Qiagen’s Clinical Insight Interpret software suite, variants are classified based on guidelines with a focus on actionable content from drug labels and clinical trials. Information is presented in a final clinical report. The whole process from samples (blood/FFPE) to clinical report is completed within 10 business days in our CLIA laboratory.

OptiSeq™ Pan-Cancer Panel is designed to target 2,900 commonly observed mutational positions (hotspots) from 65 oncogenes and tumor suppressor genes. This panel contains a single pool of 601 primer pairs and the average amplicon length is 145 bp – perfectly suitable for ctDNA and FFDNA sequencing.

OptiSeq™ Pan-Cancer Gene Panel (65 Genes)

ABL1AKT1ALKAPCATMBRAFBRCA1
BRCA2CDH1CDKN2ACSF1RCTNNB1DDR2DNMT3A
EGFRERBB2ERBB3ERBB4EZH2FBXW7FGFR1
FGFR2FGFR3FLT3FOXL2GNA11GNAQGNAS
HNF1AHRASIDH1IDH2JAK2JAK3KDR
KITKRASMAP2K1METMLH1MPLMSH6
MTORNF1NF2NOTCH1NPM1NRASPDGFRA
PIK3CAPIK3R1PTCH1PTENPTPN11RB1RET
SMAD4SMARCB1SMOSRCSTK11TERTTP53
TSC1VHL

Advantages of OptiSeq™ Pan-Cancer Panel Service

samples tested

Liquid biopsy (blood/ccfDNA) and FFPE samples (tissue/DNA)  

Clia-certified

Laboratory developed tests performed in a CLIA certified laboratory  

Fast turnaround time

Sample receipt to clinical report within 10 days. No deep sequencing  

Extremely uniform

100% observed uniformity at ≥ 0.2X mean depth and 97% observed uniformity at ≥ 0.5X

highly sensitive

As low as 1% variant allele frequency (VAF) detection  

Report to Clinicians

Comprehensive clinically significant variants, FDA approved therapies and clinical trials

Low dna input needed

10 ng for detection of somatic mutations (SNP); 100pg for germline mutations

OptiSeq™ Pan-Cancer Panel Service Sample Clinical Report

DiaCarta’s clinical report also includes information regarding variant details, FDA approved therapies for this indication, therapies associated with resistance, clinical trials, genes tested, methods and limitations and selected citations.

Streamlined Workflow for OptiSeq™ Pan-Cancer Panel

Step 1: Sample prep & QC

Step 2: Target enrichment

Step 3: Library Preparation & QC & Template

Step 4: Sequencing Run

Step 5: Data Analysis

Step 6: Reporting

OptiSeq™ Pan-Cancer Panel Specifications

Service Certification

Service performed in a CLIA-certified laboratory 

Sample Type

Liquid biopsy (blood/cfDNA) and FFPE samples (tissue/DNA)

Species

Human

Recommended DNA Input (Amount)

10ng for detection of somatic mutations (SNP); 100pg for germline mutations

Sequencing Platform

Illumina Sequencers (MiniSeq, MiSeq, NextSeq, HiSeq)

Enrichment Method

Multiplex PCR

Number of Primer Pairs

601

Number of Primer Pools

1

Number of Target Genes

65

Target Region Size (bp)

55199

Amplicon Size

Average 146bp (from 125-175bp)

Sample Multiplexing (at ~2000x mean coverage)

Miseq 2×150 Read Length: ~25 samples
NextSeq Series Mid Output 2×150 Read Length: ~200
NextSeq Series High Output @ 2×150 Read Length: ~600

Coverage Uniformity (at ~ ≥ 0.2x Mean Coverage)

> 95%

On-target Reads % (% reads aligned to target regions out of total aligned reads)

> 95%

Turnaround Time

Sample receipt to clinical report within 10 days

Resources

Need Help?

Call us: +1 (800) 878-6662

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X